Literature DB >> 20056178

Polymorphisms in innate immunity genes and patients response to dendritic cell-based HIV immuno-treatment.

Ludovica Segat1, Lucas A C Brandão2, Rafael L Guimarães2, Alessandra Pontillo3, Emmanouil Athanasakis3, Rafael Martins de Oliveira4, Luiz C Arraes5, Josè Luiz de Lima Filho2, Sergio Crovella6.   

Abstract

Dendritic cells (DCs)-based vaccine was demonstrated to increase HIV specific cellular immune response; however, in some HIV-infected patients, the response to the vaccine resulted to be not effective. In order to understand if the outcome of the vaccination may be influenced by the host's genome and natural immunity, we studied the innate immune genome of HIV-infected patients previously vaccinated with DCs. We identified 15 SNPs potentially associated with the response to the immuno-treatment and two SNPs significantly associated with the modulation of the response to the DC vaccine: MBL2 rs10824792 and NOS1 rs693534. These two SNPs were also studied in different ethnic groups (Brazilians, African and Caucasian) of HIV-infected, exposed uninfected and unexposed uninfected subjects. The HIV positive Caucasian patients were also characterized by different disease progressions. Our findings suggest that, independently and/or in addition to other variables, the host's genome could significantly contribute to the modulation of the response to the DC vaccine. Copyright 2009 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20056178     DOI: 10.1016/j.vaccine.2009.12.056

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  5 in total

1.  Host genomic HIV restriction factors modulate the response to dendritic cell-based treatment against HIV-1.

Authors:  Alessandra Pontillo; Ronaldo C Da Silva; Ronald Moura; Sergio Crovella
Journal:  Hum Vaccin Immunother       Date:  2013-11-15       Impact factor: 3.452

2.  Host genetics contributes to the effectiveness of dendritic cell-based HIV immunotherapy.

Authors:  Edione C Reis; Lais T da Silva; Wanessa C da Silva; Alexandre Rios; Alberto J Duarte; Telma M Oshiro; Sergio Crovella; Alessandra Pontillo
Journal:  Hum Vaccin Immunother       Date:  2018-05-17       Impact factor: 3.452

Review 3.  Dendritic Cell-Based Immunotherapies to Fight HIV: How Far from a Success Story? A Systematic Review and Meta-Analysis.

Authors:  Antonio Victor Campos Coelho; Ronald Rodrigues de Moura; Anselmo Jiro Kamada; Ronaldo Celerino da Silva; Rafael Lima Guimarães; Lucas André Cavalcanti Brandão; Luiz Cláudio Arraes de Alencar; Sergio Crovella
Journal:  Int J Mol Sci       Date:  2016-11-26       Impact factor: 5.923

Review 4.  Using Dendritic Cell-Based Immunotherapy to Treat HIV: How Can This Strategy be Improved?

Authors:  Laís Teodoro da Silva; Bruna Tereso Santillo; Alexandre de Almeida; Alberto Jose da Silva Duarte; Telma Miyuki Oshiro
Journal:  Front Immunol       Date:  2018-12-18       Impact factor: 7.561

5.  Exome analysis of HIV patients submitted to dendritic cells therapeutic vaccine reveals an association of CNOT1 gene with response to the treatment.

Authors:  Ronald Moura; Alessandra Pontillo; Pio D'Adamo; Nicola Pirastu; Antonio Campos Coelho; Sergio Crovella
Journal:  J Int AIDS Soc       Date:  2014-01-10       Impact factor: 5.396

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.